Skip to main content

Table 5 Findings from the sensitivity analyses

From: The cost-effectiveness of hospital-based telephone coaching for people with type 2 diabetes: a 10 year modelling analysis

   Quality adjusted life expectancy (QALYs) Direct healthcare costs (2012/13 Australian dollars) ICER (Cost per QALY)
Intervention group (n = 47) Control group (n = 47) Difference Intervention group (n = 47) Control group (n = 47) Difference  
Base-case   4.9 (4.5–5.2) 4.7 (4.4–5.0) 0.2 (0–0.3) 59,790 (48,182–71,399) 63,117 (41,490–84,745) −3327 (−27,645–20,991) Dominant
Time horizon Two years 1.4 (1.3–1.4) 1.4 (1.3–1.4) 0.0 (−0.1–0.1) 16,581 (12,619–20,543) 20,440 (12,436–28,445) −3859 (−12,715–4997) $3859 saved Nil benefit
Five years 3.1 (2.9–3.2) 3.0 (2.8–3.1) 0.1 (−0.2–0.3) 36,801 (28,599–45,003) 41,562 (26,330–56,795) −4761 (−21,901–12,378) Dominant
15 years 6.9 (6.2–7.5) 6.5 (5.8–7.1) 0.4 (−0.5–1.3) 85,014 (70,189–99,838) 85,124 (57,566–112,681) −110 (−31,111–30,890) Dominant
Discount rate 0 % 6.2 (5.8–6.7) 5.9 (5.5–6.4) 0.3 (−0.3–0.9) 73,839 (59,390–88,288) 78,987 (52,235–105,739) −5148 (−35,268–24,972) Dominant
3 % 5.4 (5.0–5.7) 5.2 (4.8–5.5) 0.2 (−0.3–0.8) 65,125 (52,499–77,750) 68,797 (45,334–92,261) −3673 (−30,070–22,724) Dominant
6 % 4.7 (4.4–5.0) 4.5 (4.2–4.8) 0.2 (−0.3–0.6) 56,800 (45,654–67,946) 60,556 (39,758–81,354) −3756 (−27,134–19,622) Dominant
Utility scores Lower limit of 95 % CI 4.8 (4.5–5.2) 4.6 (4.3–5.0) 0.2 (−0.3–0.7) 59,790 (48,182–71,399 63,117 (41,490–84,745) −3327 (−27,645–20,991) Dominant
Upper limit of 95 % CI 4.9 (4.6–5.2) 4.7 (4.4–5.0) 0.2 (−0.3–0.7) 59,790 (48,182–71,399 63,117 (41,490–84,745) −3327 (−27,645–20,991) Dominant
Cost of complications Lower limit of 95 % CI 4.9 (4.5–5.2) 4.7 (4.4–5.0) 0.2 (0–0.3) 53,979 (45,646–62,311) 52,493 (36,526–68,460) 1485 (−16,285–19,256) $7425 per QALY
Upper limit of 95 % CI 4.9 (4.5–5.2) 4.7 (4.4–5.0) 0.2 (0–0.3) 66,455 (51,397–81,513) 74,526 (47,419–101,633) −8071 (−38,667–22,524) Dominant
Cost – no complications Lower limit of 95 % CI 4.9 (4.5–5.2) 4.7 (4.4–5.0) 0.2 (−0.3–0.7) 45,347 (32,674–58,020) 61,116 (39,199–83,034) −15,769 (−40,833–9294) Dominant
Upper limit of 95 % CI 4.9 (4.7–5.1) 4.7 (4.4–4.9) 0.2 (−0.3–0.7) 74,261 (62,640–85,881) 65,139 (43,796–86,483) 9121 (−14,951–33,194) $45,605 per QALY
HbA1C HbA1C maintained for one simulation year 4.9 (4.7–5.1) 4.7 (4.4–4.9) 0.2 (−0.3–0.7) 59,931 (48,276–71,586) 63,214 (41,475–84,953) −3283 (−27,721–21,155) Dominant
HbA1C maintained for two simulation years 4.9 (4.7–5.1) 4.7 (4.4–4.9) 0.2 (−0.3–0.7) 59,986 (48,307–71,665) 62,628 (41,116–84,140) −2642 (−26,890–21,606) Dominant
HbA1C maintained for five simulation years 4.9 (4.7–5.1) 4.7 (4.4–4.9) 0.2 (−0.3–0.7) 60,014 (48,343–71,685) 62,974 (41,251–84,696) −2960 (−27,390–21,470) Dominant
Stroke Nil past history of stroke in either group 4.9 (4.5–5.2) 4.7 (4.3–5.0) 0.2 (−0.3–0.7) 59,134 47,497–70,771 58,261 (38,557–77,966) 873 (−21,778–23,523) $4365 per QALY
  1. Mean (95 % CI) unless otherwise specified